Drug Profile
Research programme: rheumatoid arthritis therapy - Five Prime Therapeutics/Boehringer Ingelheim
Latest Information Update: 21 Apr 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Five Prime Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 16 Apr 2021 Five Prime Therapeutics has been acquired by Amgen
- 21 Feb 2011 No development reported - Preclinical for Rheumatoid arthritis in Germany (unspecified route)
- 21 Feb 2011 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)